1. A portable nasal aspiration system for removing secretion from a user’s nasal canals, comprising:
a sealed, detachable vacuum canister having an attachment device;
two aspiration tubes for inserting into a users nasal canal, each with one inlet and one outlet;
a cap forming two apertures spaced apart and supporting the two aspiration tubes, each inlet of the aspiration tubes aligned with a different one of the two apertures such that fluid passes through each aperture independently, a distance between the two aspiration tubes being adjustable to align the aspiration tubes with a user’s nasal canals;
a port, comprising:
a valve within the port for controlling flow of fluid from the two aspiration tubes, through the port and to the detachable vacuum canister,
a first attachment end for attaching the port to the cap such that the two apertures are in fluid communication with the valve; and
a second attachment end for attaching the port to the vacuum canister attachment device such that the valve, when operated, is in fluid communication with a vacuum within the vacuum canister,
wherein the vacuum canister is sealed and retains a vacuum prior to attaching the vacuum canister attachment device to the second attachment end of the port.
2. The system of claim 1, further comprising an adjustable slider for adjusting the distance between the two aspiration tubes.
3. The system of claim 1, the valve comprising:
a conduit having a rigid pointed end;
an attachment mechanism served to block at least one outlet formed on the conduit and to connect the port to the attachment device of the vacuum canister; and
at least one spring compressed to move the conduit through the attachment mechanism to unblock the at least one outlet, thereby placing the at least one outlet in an operational position.
4. The system of claim 1, wherein the attachment device of the detachable vacuum canister having an aperture thereon, and further comprising a protective film being disposed with the aperture to retain the vacuum within the vacuum canister and penetrable to activate the canister.
5. The nasal aspiration system of claim 1, further comprising attachment straps for fastening the nasal aspiration system to a user.
6. The nasal aspiration system of claim 1, further comprising at least two disposable nasal occluders to cover the aspiration tubes.
7. The nasal aspiration system of claim 1, further comprises attachment mechanisms that connect the first and second attachment ends of the port with the cap and the vacuum canister to form the nasal aspiration system.
8. The nasal aspiration system of claim 7, wherein the attachment mechanisms are selected from a group consisting of one or more notches, snaps, clasps, protrusions, pipes, indentations, apertures, recesses, taps, clips, adhesives, and combination thereof.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula I:
wherein;
Q is halogen;
R1 is CH2NRbRc;
R2, R3, R4 and R5 are independently selected from hydrogen and C1-3alkyl;
R6 is hydrogen or C1-6alkyl;
R7 is selected from hydrogen, C1-6alkyl, C1-6alkylaryl, aryl and heteroaryl, said C1-6alkyl, C1-6alkylaryl, aryl and heteroaryl are optionally substituted with one or more A;
A is halo, CN, ORa or NRbRc;
Ra is hydrogen, C1-3alkyl or C1-3haloalkyl, said C1-3alkyl or C1-3haloalkyl is optionally substituted with one or more C1-3alkoxy;
Rb and Rc may, together with the atom to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or more halo, C1-3alkyl or C1-3haloalkyl, and in which any sulphur atom is optionally oxidised to \u2014SO2\u2014;
as a base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.
2. A compound according to claim 1, wherein said halogen in Q is selected from bromo, chloro and fluoro.
3. A compound according to claim 1, wherein said RbRc together with the atom to which they are attached, form a 6-membered heterocyclic ring containing one or more heteroatoms selected from N or O.
4. A compound according to any one of claims 1 to 3, wherein said R2, R3, R4 and R5 are hydrogen.
5. A compound according to any one of claims 1 to 3, wherein R6 is hydrogen and R7 is C1-6alkyl, said C1-6alkyl being optionally substituted with one or more A.
6. A compound according to claim 5, wherein A is ORa.
7. A compound according to claim 6, wherein said R2 in ORa represents C1-3alkyl.
8. A compound according to claim 1, wherein Q is halogen; R1 is CH2NRbRc, RbRc together with the atom to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S; R2, R3, R4 and R5 are hydrogen; R6 is hydrogen and R7 is C1-6alkyl, said C1-6alkyl is substituted with one A, said A being ORa, said Ra in ORa representing C1-3alkyl.
9. A compound according to claim 1, wherein Q is halogen; R1 is CH2NRbRc, RbRc together with the atom to which they are attached, form a 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S; R2, R3, R4 and R5 are hydrogen; R6 is hydrogen and R7 is C1-6alkyl, said C1-6alkyl is substituted with one A, said A being ORa, wherein said Ra is C1-3alkyl.
10. A compound according to claim 1, wherein Q is halogen; R1 is CH2NRbRc, RbRc together with the atom to which they are attached, form a morpholine; R2, R3, R4 and R5 are hydrogen; R6 is hydrogen and R7 is C1-6alkyl, said C1-6alkyl is substituted with one A, said A being ORE, wherein said Ra is C1-3alkyl.
11. A compound according to claim 1, selected from:
6-Bromo-N-(3-methoxypropyl)-2-4-(morpholin-4-ylmethyl)phenyl-3H-imidazo4,5-bpyridine-7-carboxamide hydrochloride;
6-Chloro-N-(3-methoxypropyl)-2-4-(morpholin-4-ylmethyl)phenyl-3H-imidazo4,5-bpyridine-7-carboxamide hydrochloride;
6-Fluoro-N-(3-methoxypropyl)-2-4-(morpholin-4-ylmethyl)phenyl-3H-imidazo4,5-bpyridine-7-carboxamide;
as a base or an alternative pharmaceutically acceptable salt, solvate or solvate of a salt thereof.
12-14. (canceled)
15. A compound selected from:
Methyl 4-(6-bromo-3H-imidazo4,5-bpyridin-2-yl)benzoate;
Methyl 4-(6-chloro-3H-imidazo4,5-bpyridin-2-yl)benzoate;
Methyl 4-(6-bromo-7-chloro-3H-imidazo4,5-bpyridin-2-yl)benzoate;
Methyl 4-(6,7-dichloro-3H-imidazo4,5-bpyridin-2-yl)benzoate;
Methyl 4-(7-chloro-6-fluoro-3H-imidazo4,5-bpyridin-2-yl)benzoate;
Methyl 4-(6-bromo-7-iodo-3H-imidazo4,5-bpyridin-2-yl)benzoate;
Methyl 4-(6-chloro-7-iodo-3H-imidazo4,5-bpyridin-2-yl)benzoate;
Methyl 4-(6-fluoro-7-iodo-3H-imidazo4,5-bpyridin-2-yl)benzoate
4-(6-Bromo-7-iodo-3H-imidazo4,5-bpyridin-2-yl)benzoic acid;
4-(6-Chloro-7-iodo-3H-imidazo4,5-bpyridin-2-yl)benzoic acid;
4-(6-Fluoro-7-iodo-3H-imidazo4,5-bpyridin-2-yl)benzoic acid
6-Bromo-7-iodo-2-4-(morpholin-4-ylcarbonyl)phenyl-3H-imidazo4,5-bpyridine;
6-Chloro-7-iodo-2-4-(morpholin-4-ylcarbonyl)phenyl-3H-imidazo4,5-bpyridine;
6-Fluoro-7-iodo-2-4-(morpholin-4-ylcarbonyl)phenyl-3H-imidazo4,5-bpyridine
6-Bromo-7-iodo-2-4-(morpholin-4-ylmethyl)phenyl-3H-imidazo4,5-bpyridine;
6-Chloro-7-iodo-2-4-(morpholin-4-ylmethyl)phenyl-3H-imidazo4,5-bpyridine and
6-Fluoro-7-iodo-2-4-(morpholin-4-ylmethyl)phenyl-3H-imidazo4,5-bpyridine.
16. A compound according to any one of claim 4, wherein R6 is hydrogen and R7 is C1-6alkyl, said C1-6alkyl being optionally substituted with one or more A.
17. A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of a compound according to in claim 1 or claim 11 in association with pharmaceutically acceptable excipients, carriers or diluents.
18. A method of prevention andor treatment of bone-related disorders including osteoporosis and increased bone formation, comprising administering to a human in need of such prevention andor treatment a therapeutically effective amount of a compound as defined in claim 1 or claim 11.